Prostate Cancer clinical trials in Hawaii

3 actively recruiting prostate cancer trials at 6 sites across Hawaii.

Data from ClinicalTrials.gov · last refreshed 2026-11-09

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology

NCT ID: NCT05946213

Sites in Hawaii:

Hawaii Cancer Care Inc - Waterfront Plaza — Honolulu, Hawaii
Queen's Cancer Cenrer - POB I — Honolulu, Hawaii
Queen's Medical Center — Honolulu, Hawaii
Straub Clinic and Hospital — Honolulu, Hawaii
University of Hawaii Cancer Center — Honolulu, Hawaii

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group

NCT ID: NCT06592924

Sites in Hawaii:

Hawaii Cancer Care Inc - Waterfront Plaza — Honolulu, Hawaii
Queen's Cancer Cenrer - POB I — Honolulu, Hawaii
Queen's Medical Center — Honolulu, Hawaii
Straub Clinic and Hospital — Honolulu, Hawaii
University of Hawaii Cancer Center — Honolulu, Hawaii

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received docetaxel chemo…

Sponsor: AstraZeneca

NCT ID: NCT07711002

Sites in Hawaii:

Research Site — Honolulu, Hawaii

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09